Please sign in to follow a disease.

8,000-Patient trial aims to find best way to beat deadly staph blood infection

NCT ID NCT05137119

Disease control Sponsor: University of Melbourne Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This massive international trial is testing several antibiotics and treatment strategies to find the best way to reduce deaths from Staphylococcus aureus bloodstream infections. About 8,000 hospitalized adults with a confirmed staph blood infection will be randomly assigned to different antibiotics or approaches, including early switching to oral pills or using PET/CT scans to guide treatment. The main goal is to see which approach lowers the chance of death within 90 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Various antibiotics (cefazolin, penicillin, clindamycin, vancomycin/daptomycin) and strategies (early switch to oral antibiotics, PET/CT imaging)
What this could lead to: If successful, this trial could identify the best antibiotic combinations and strategies to lower the death rate from serious staph bloodstream infections.
What could go wrong: This is a large, late-stage trial, but results depend on many variables and may not apply to all patients. Antibiotic resistance or side effects could limit benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 8,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PLATFORM Inclusion Criteria: Patients must fulfil all of the following criteria to be eligible to enter the SNAP trial: 1. Staphylococcus aureus complex grown from ≥1 blood culture 2. Admitted to a participating hospital at the time of eligibility assessment (OR if patient has died, they were admitted to this site anytime from the time of blood culture collection until the time of eligibility assessment) PLATFORM Exclusion Criteria: Potentially eligible participants meeting any of the following criteria at the time of eligibility assessment for platform entry will be excluded from the randomised platform (but may still participate in the registry): 1. Time of anticipated platform entry is greater than 72 hours post collection of the index blood culture (Where the time of culture collection is not recorded, the time of laboratory registration of the sample will be used as an alternative) 2. Polymicrobial bacteraemia, defined as more than one organism (at species level) in the index blood cultures OR in any subsequent blood culture reported between the collection of the index blood culture and platform eligibility assessment, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician. 3. Known previous participation in the randomised SNAP platform 4. Known positive blood culture for S. aureus (of the same silo: PSSA, MSSA or MRSA) between 72 hours and 180 days prior to the time of eligibility assessment 5. Treating team deems enrolment in the study is not in the best interest of the patient 6. Treating team believes that death is imminent and inevitable 7. Patient is for end-of-life care and antibiotic treatment is considered not appropriate 8. Patient \<18 years of age and paediatric recruitment not approved at recruiting site 9. Patient has died since the collection of the index blood culture To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above) ADJUNCTIVE TREATMENT DOMAIN Inclusion Criteria: 1. All participants that met the PLATFORM eligible are eligible to be included in this domain unless they meet any of the following exclusions listed. 2. Patients are eligible for this domain regardless of S. aureus susceptibility testing results to clindamycin. Exclusion criteria: 1\. Previous type 1 hypersensitivity reaction to lincosamides 2. Currently receiving clindamycin (lincomycin) or linezolid which cannot be ceased or substituted 3. Necrotising fasciitis 4. Current C. difficile associated diarrhoea (any severity) 5. Current severe diarrhoea from any cause (defined as Grade 3 or higher) 5. Known CDAD (C.Difficile Associated Diarrhoea) in the past 3 months, or CDAD relapse in the past 12 months 6. At the time of domain eligibility assessment, more than 4 hours has elapsed since platform entry 7. Treating clinician deems enrolment in this domain is not in the best interest of the patient PSSA, MSSA TREATMENT DOMAIN (backbone) Inclusion Criteria: 1. For PSSA silo: Index blood culture isolate is penicillin-susceptible as per the Microbiology Appendix. In short, this will require phenotypic disc testing with EUCAST (a P1 disc diffusion with zone \>=26mm OR a P1 disc diffusion with zone \>=26mm and the zone edge is NOT sharp) OR CLSI (a P10 disc diffusion) defined criteria. 2. For MSSA silo: Index blood culture isolate is methicillin-susceptible as per the Microbiology Appendix. Note that where trial sites are not testing for penicillin-susceptibility, patients with MSSA/PRSA can be included in the MSSA silo, but those with MSSA/PSSA (but not confirmed with a P-disc) will be excluded from the backbone domain. The rationale for this is that patients with MSSA but not tested with a P-disc may be truly PSSA (with no blaZ). If the cefazolin inoculum effect (CIE) is a clinically relevant entity, then including patients with an organism without blaZ (and hence cannot have a CIE phenotype), will bias towards non-inferiority of cefazolin compared to (flu)cloxacillin. For PSSA, the requirement for laboratories to use an accredited phenotypic test for a penicillin-susceptible phenotype, is to ensure clinical safety according to internationally accepted guidelines. The automated antimicrobial susceptibility testing, and other phenotypic tests, have poor sensitivity for detection of blaZ compared to a gold standard of blaZ PCR. Therefore, patients could be placed at risk of treatment with benzylpenicillin when the infecting isolate is actually blaZ positive, unless these guidelines are followed. Exclusion Criteria (PSSA \& MSSA): 1. \>72 hours have elapsed since the collection of the index blood culture (i.e. the time of collection of the first positive blood culture from the patient during this episode) 2. History of type I hypersensitivity reaction (i.e. anaphylaxis or angioedema) to any penicillin or cephalosporin 3. History of severe delayed reaction (e.g. allergic interstitial nephritis, cutaneous vasculitis, Stevens-Johnson, DRESS, etc.) to any penicillin or cephalosporin 4. PSSA silo: Non-severe rash to any penicillin (unless patient has been subsequently de-labelled; this criteria does not include criteria 2 and 3 above), or MSSA silo: Non-severe rash to cefazolin or any penicillin (unless patient has been subsequently de-labelled); (Nausea, diarrhoea, headache, and other non-specific symptoms are NOT allergies, they are drug intolerance, and they are not exclusion criteria. Similarly, a vague history of an allergy of unclear nature, or a family history of allergy are not exclusions.) 5. Treating team deems enrolment in this domain is not in the best interest of the patient 6. Currently receiving maintenance dialysis (haemodialysis or peritoneal dialysis); (Acute renal replacement therapy (including CRRT, haemodialysis or peritoneal dialysis) are not exclusions. Such patients are eligible as long as appropriate vascular access is available or can be arranged.) 7. Polymicrobial bacteraemia (defined as more than one organism \[at species level\] in blood cultures, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician) reported between collection of the index blood culture and backbone domain eligibility assessment 8. Patient currently being treated with a systemic antibacterial agent that cannot be ceased or substituted for interventions allocated within the platform (unless antibiotic is listed in Table 1 of the DSA, which specifies allowed antibiotics with limited absorption from the gastrointestinal tract or negligible antimicrobial activity against S. aureus) MRSA TREATMENT DOMAIN (backbone) Inclusion Criteria: 1\. MRSA confirmed microbiologically Exclusion Criteria: 1. Time to allocation reveal is \>72 hours from time of index blood culture collection 2. Severe allergy to any beta-lactam (including cefazolin) Immediate severe allergy: Anaphylaxis/angioedema Severe delayed allergy: Severe cutaneous adverse reaction (SCAR; including Steven Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) and acute generalised exanthematous pustulosis (AGEP)), severe drug induced liver injury, proven allergic interstitial nephritis, immune-mediated haemolytic anaemia and other severe cytopenia. 3. Non-severe rash to cefazolin Nausea, diarrhoea, headache and other non-specific symptoms are NOT allergies, they are drug intolerance, and they are not exclusion criteria. Similarly, a vague history of an allergy of unclear nature, or a family history of allergy are not exclusions.) 3\. Severe allergy or non-severe rash to both vancomycin AND daptomycin Vancomycin infusion reaction (formerly known as "red man syndrome") is due to direct histamine release and is not generally an allergy, and therefore is not considered an exclusion. 5\. Treating team deems enrolment in the domain is not in the best interest of the patient 6. Polymicrobial bacteraemia (defined as more than one organism \[at species level\] in blood cultures, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician) reported between collection of the index blood culture and backbone domain eligibility assessment. 7\. Patient currently being treated with a systemic antibacterial agent that cannot be ceased or substituted for interventions allocated within the platform (unless antibiotic is listed in Table 1 of the DSA, which specifies allowed antibiotics with limited absorption from the gastrointestinal tract or negligible antimicrobial activity against S. aureus) EARLY ORAL SWITCH DOMAIN Inclusion Criteria: Day 7 (+/- 2 days): 1. Clearance of SAB by platform Day 2: blood cultures negative for S. aureus from platform Day 2 onwards AND no known subsequent positive blood cultures 2. Afebrile (\<37.8°C) for the past 72 hours (at time of judging eligibility) 3. Primary focus is either line related (either central or peripheral IV cannula) or skin and soft tissue, AND source control achieved (for 'line-related' this means line removed; for 'skin and soft tissue' means site PI considers source control to have been achieved and any abscess more than 2cm diameter has been drained) 4. No evidence of metastatic foci (on clinical or radiological examination, but radiological imaging is not required to exclude metastatic foci if not clinically indicated) Day 14 (+/- 2 days): 1. Clearance of SAB by platform Day 5: blood cultures negative for S. aureus from platform Day 5 (+/-1 day) AND no known subsequent positive blood cultures. If the most recent blood culture from Day 2-4 is negative for S. aureus, blood cultures do not need to be repeated on Day 5 to fulfil eligibility criteria (Day 5 blood cultures will be assumed to be negative in this situation) 2. Afebrile (\<37.8°C) for the past 72 hours (at time of judging eligibility) 3. Site Principal Investigator has determined that source control is adequate Exclusion Criteria: When judging eligibility at platform Day 7 (+/- 2 days) and at Day 14 (+/- 2 days), exclusion criteria are: 1. Adherence to oral agents unlikely (as judged by site PI in consultation with the treating team) 2. Unreliable gastrointestinal absorption (e.g. vomiting, diarrhoea, nil by mouth, anatomical reasons) 3. There are no appropriate oral antibiotics due to contraindications, drug availability, or antibiotic resistance 4. Ongoing IV therapy unsuitable e.g. no IV access 5. Clinician deems not appropriate for early oral switch 6. Patient no longer willing to participate in domain In the lead-up to judging eligibility, it may be helpful to discuss with the patient the potential for continued IV treatment versus oral switch, to allow hospital discharge planning 7. Clinical team deems that sufficient duration of antibiotic therapy has already been provided Exclusions when judging eligibility for early oral switch at trial Day 7 (+/- 2 days): 1. Presence of prosthetic cardiac valve, pacemaker or other intracardiac implant 2. Presence of intravascular clot, graft, or other intravascular prosthetic material Intravascular clot excludes superficial peripheral IV line-related thrombophlebitis. Intravascular prosthetic material excludes coronary artery stents) 3. Intravascular/intracardiac infections (e.g. endocarditis, mycotic aneurysm) 4. Presence of other intracardiac abnormalities felt to put patient at increased risk of endocarditis (e.g., bicuspid aortic valve) PET/CT DOMAIN Inclusion Criteria: 1. PET/CT participating site 2. Patient is accessible for PET/CT - a patient is considered accessible if the site team are able to access the participant medical records, arrange for a PET/CT scan for the patient, and discuss this domain with the patient and their treating healthcare providers. Exclusion Criteria: 1. Pregnant - patients of childbearing potential should be assessed for pregnancy status and a pregnancy test performed (if not performed within the past 10 days) 2. Currently breastfeeding 3. \< 18 years of age 4. Patient has had PET/CT in the past 7 days 5. Patient needs PET/CT in the next 7 days (in the opinion of the clinical team, at the time of eligibility assessment) 6. Clinically unstable for PET/CT (as judged by the treating clinical team, taking into account need for organ support (including inotropes) and capacity to lie flat for the PET/CT) 7. Contraindication to PET/CT (e.g., claustrophobia, persistently elevated blood sugar levels \[\>12.5mmol/L\] that cannot be corrected). 8. Patient no longer willing to participate in the domain - in the days leading up to judging eligibility, it may be helpful to discuss with the patient the potential for PET/CT vs no PET/CT to allow imaging planning 9. Clinician deems participation in this domain is not in the patient's best interests

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

staphylococcal infection staphylococcus aureus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Staphylococcus aureus bacteremia

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

153 sites in 13 countries. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

Alfred Hospital
RECRUITING

Melbourne, Victoria, 3004, Australia
Antonius Ziekenhuis
RECRUITING

Nieuwegein, Netherlands
Armadale Hospital
RECRUITING

Perth, Western Australia, 6112, Australia
Auckland City Hospital
RECRUITING

Grafton, Auckland, 1023, New Zealand
Austin Hospital
RECRUITING

Heidelberg, Victoria, 3084, Australia
Barts Health
RECRUITING

London, United Kingdom
Barwon Health - University Hospital Geelong
RECRUITING

Geelong, Victoria, 3220, Australia
Beilinson Hospital
RECRUITING

Petah Tikva, 49100, Israel
Bendigo Health
RECRUITING

Bendigo, Victoria, 3550, Australia
Blacktown Hospital
RECRUITING

Blacktown, New South Wales, 2148, Australia
Box Hill Hospital
RECRUITING

Box Hill, Victoria, 3128, Australia
Brighton and Sussex University Hospitals
RECRUITING

Brighton, United Kingdom
CHU de Rennes - Hôpital Pontchaillou
RECRUITING

Rennes, France
CISSS - Hôpital Cité-de-la-Santé Hospital
RECRUITING

Laval, Quebec, Canada
Cairns Hospital
RECRUITING

Cairns, Queensland, 4870, Australia
Cambridge University Hospitals
NOT_YET_RECRUITING

Cambridge, United Kingdom
Canberra Hospital
RECRUITING

Garran, Australia Capital Territory, 2605, Australia
Cardiff and Vale University
RECRUITING

Cardiff, United Kingdom
Charité University Hospital Berlin
RECRUITING

Berlin, Germany
Charlotte Maxeke Johannesburg Academic Hospital
NOT_YET_RECRUITING

Johannesburg, South Africa
Christchurch Hospital
NOT_YET_RECRUITING

Christchurch, Canterbury, 8011, New Zealand
Concord Repatriation and General Hospital
RECRUITING

Concord, New South Wales, 2139, Australia
Eastern Health - Health Sciences Centre (Memorial University)
RECRUITING

St. John's, Newfoundland and Labrador, A1B3V6, Canada
Eastern Regional Health Authority - St. Clare's Mercy Hospital
RECRUITING

St. John's, Newfoundland and Labrador, Canada
Fiona Stanley Hospital
RECRUITING

Murdoch, Western Australia, 6150, Australia
Flinders Medical Centre
RECRUITING

Bedford Park, South Australia, 5042, Australia
Foothills Medical Center
RECRUITING

Calgary, Alberta, T2N4Z6, Canada
Frankston Hospital
NOT_YET_RECRUITING

Frankston, Victoria, 3199, Australia
Fraser Health Authority - Surrey Memorial Hospital
RECRUITING

Surrey, British Columbia, Canada
Gold Coast University Hospital
RECRUITING

Southport, Queensland, 4215, Australia
Goulburn Valley Health
COMPLETED

Shepparton, Victoria, 3630, Australia
Grace Hospital
RECRUITING

Winnipeg, Manitoba, R3J 3M7, Canada
Grampians Health
RECRUITING

Ballarat, Victoria, 3350, Australia
Great Ormond Street
NOT_YET_RECRUITING

London, United Kingdom
Greater Glasgow and Clyde
NOT_YET_RECRUITING

Glasgow, United Kingdom
Guys and St Thomas'
RECRUITING

London, United Kingdom
Hamilton Health Sciences - Hamilton General Hospital
RECRUITING

Hamilton, Ontario, L8P1A2, Canada
Hamilton Health Sciences - Juravinski Hospital
RECRUITING

Hamilton, Ontario, Canada
Health Sciences Centre Winnipeg
RECRUITING

Winnipeg, Manitoba, R3A1R9, Canada
Helen Joseph Hospital
ACTIVE_NOT_RECRUITING

Johannesburg, South Africa
Helsingborg Hospital
RECRUITING

Helsingborg, Sweden
Houston Methodist Research Institute
RECRUITING

Houston, Texas, 77030, United States
Hull University Teaching Hospitals
RECRUITING

Hull, United Kingdom
Hutt Valley Hospital
RECRUITING

Boulcott, Lower Hutt, 5010, New Zealand
Hôpital Régional de Saint Jérôme
RECRUITING

Saint-Jérôme, Quebec, J7Z5T3, Canada
Ikazia Ziekenhuis
RECRUITING

Rotterdam, Netherlands
Imperial College Healthcare
RECRUITING

London, United Kingdom
Ipswich Hospital
RECRUITING

Ipswich, Queensland, 4305, Australia
Jeroen Bosch Hospital
RECRUITING

's-Hertogenbosch, Netherlands
Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T1E2, Canada
John Hunter Children's Hospital
RECRUITING

Newcastle, New South Wales, 2305, Australia
John Hunter Hospital
RECRUITING

New Lambton Heights, New South Wales, 2305, Australia
KidzFirst
RECRUITING

Auckland, 2025, New Zealand
Kings College Hospital
NOT_YET_RECRUITING

London, United Kingdom
Kingston Health Sciences Centre - Kingston General Hospital
RECRUITING

Kingston, Ontario, K7L2V7, Canada
La Trobe Regional Hospital
NOT_YET_RECRUITING

Traralgon, Victoria, 3844, Australia
Launceston Hospital
RECRUITING

Launceston, Tasmania, 7250, Australia
Leeds Teaching Hospitals
RECRUITING

Leeds, United Kingdom
Liverpool Hospital
RECRUITING

Liverpool, New South Wales, 2170, Australia
Liverpool University Hospital
RECRUITING

Liverpool, United Kingdom
Logan Hospital
NOT_YET_RECRUITING

Meadowbrook, Queensland, 4131, Australia
London Health Sciences Centre - University Hospital, LHSC
COMPLETED

London, Ontario, Canada
Lothian Western General
RECRUITING

Edinburgh, United Kingdom
Lyell McEwin Hospital
RECRUITING

Adelaide, South Australia, 5112, Australia
Maastricht UMC+
RECRUITING

Maastricht, Netherlands
Manchester University Hospitals
RECRUITING

Manchester, United Kingdom
McGill University Health Centre - Montral General Hospital
RECRUITING

Montreal, Quebec, H4A3J1, Canada
McGill University Health Centre - Montreal Children's Hospital
NOT_YET_RECRUITING

Montreal, Quebec, Canada
McGill University Health Centre - Royal Victoria Hospital
RECRUITING

Montreal, Quebec, Canada
Middlemore Hospital
RECRUITING

Otahuhu, Auckland, 1640, New Zealand
Monash Children's Hospital
NOT_YET_RECRUITING

Clayton, Victoria, 3168, Australia
Monash Health - Monash Medical Centre & Jesse McPherson Private Hospital
RECRUITING

Clayton, Victoria, 3168, Australia
NHS Forth Valley
NOT_YET_RECRUITING

Stirling, United Kingdom
NHS Golden Jubilee
NOT_YET_RECRUITING

Glasgow, United Kingdom
NHS Grampian
NOT_YET_RECRUITING

Aberdeen, United Kingdom
NHS Tayside
NOT_YET_RECRUITING

Dundee, United Kingdom
National University Hospital
RECRUITING

Singapore, 119228, Singapore
Nepean Hospital
RECRUITING

Kingswood, New South Wales, 2747, Australia
Newcastle Upon Tyne Hospitals
RECRUITING

Newcastle upon Tyne, United Kingdom
Niagara Health - Niagara Falls Site
RECRUITING

Niagara Falls, Ontario, Canada
Niagara Health - St. Catharines Site
RECRUITING

St. Catharines, Ontario, L2S 0A9, Canada
North Bristol
RECRUITING

Bristol, United Kingdom
North Shore Hospital
RECRUITING

Takapuna, Auckland, 0620, New Zealand
Nottingham University Hospitals
NOT_YET_RECRUITING

Nottingham, United Kingdom
Orange Health Service
RECRUITING

Orange, New South Wales, 2800, Australia
Otto-von-Guericke-university Magdeburg
RECRUITING

Magdeburg, Germany
Oxford University Hospitals
RECRUITING

Oxford, United Kingdom
Perth Children's Hospital
RECRUITING

Nedlands, Western Australia, 6009, Australia
Peter Lougheed Centre
RECRUITING

Calgary, Alberta, T1Y 6J4, Canada
Prince of Wales Hospital
RECRUITING

Randwick, New South Wales, 2031, Australia
Princess Alexandra Hospital
NOT_YET_RECRUITING

Woolloongabba, Queensland, 4102, Australia
Queensland Children's Hospital
RECRUITING

South Brisbane, Queensland, 4101, Australia
Radboud University Medical Center
RECRUITING

Nijmegen, Netherlands
Rahima Moosa Mother and Child Hospital
NOT_YET_RECRUITING

Johannesburg, South Africa
Rambam Health Care Campus
RECRUITING

Haifa, 310960, Israel
Redcliffe Hospital
RECRUITING

Redcliffe, Queensland, 4020, Australia
Richmond Hospital
RECRUITING

Richmond, British Columbia, V6X1A2, Canada
Rijnstate Hospital
ACTIVE_NOT_RECRUITING

Arnhem, Netherlands
Robina Hospital
RECRUITING

Robina, Queensland, 4226, Australia
Rockyview Hospital
RECRUITING

Calgary, Alberta, T2V 1P9, Canada
Royal Brisbane and Women's Hospital
RECRUITING

Herston, Queensland, 4029, Australia
Royal Children's Hospital Melbourne
RECRUITING

Parkville, Victoria, 3052, Australia
Royal Cornwall Hospitals
NOT_YET_RECRUITING

Cornwall, United Kingdom
Royal Darwin Hospital
RECRUITING

Tiwi, Northern Territory, 0811, Australia
Royal Devon University Healthcare
NOT_YET_RECRUITING

Devon, United Kingdom
Royal Free London
RECRUITING

London, United Kingdom
Royal Hobart Hospital
NOT_YET_RECRUITING

Hobart, Tasmania, 7000, Australia
Royal Melbourne Hospital
RECRUITING

Parkville, Victoria, 3050, Australia
Royal Perth Hospital
RECRUITING

Perth, Western Australia, 6000, Australia
Royal Prince Alfred Hospital
RECRUITING

Camperdown, New South Wales, 2050, Australia
SUS Malmö
RECRUITING

Malmö, Sweden
Sault Area Hospital
COMPLETED

Sault Ste. Marie, Ontario, P6B 0A8, Canada
Schneider Hospital
RECRUITING

Petah Tikva, Israel
Science Tokyo University Hospital
RECRUITING

Ichikawa, Chiba, 272-0827, Japan
Sheba Medical Centre
RECRUITING

Ramat Gan, 49100, Israel
Sheffield Teaching Hospitals
NOT_YET_RECRUITING

Sheffield, United Kingdom
Sinai Heath System - Mount Sinai Hospital
RECRUITING

Toronto, Ontario, M5G1X5, Canada
Singapore General Hospital
RECRUITING

Singapore, 168753, Singapore
South Health Campus
RECRUITING

Calgary, Alberta, T3M 1M4, Canada
South Tees Hospitals
RECRUITING

South Tees, United Kingdom
St George Hospital
NOT_YET_RECRUITING

Kogarah, New South Wales, 2217, Australia
St Vincent's Hospital Sydney
RECRUITING

Darlinghurst, New South Wales, 2010, Australia
St. Boniface Hospital
RECRUITING

Winnipeg, Manitoba, R2H 2A6, Canada
Starship Hospital
RECRUITING

Auckland, 1023, New Zealand
Sunnybrook Health Sciences Centre
RECRUITING

Toronto, Ontario, M4N3M5, Canada
Sunshine Coast University Hospital
RECRUITING

Birtinya, Queensland, 4575, Australia
Swansea Bay University Health Board
RECRUITING

Swansea, United Kingdom
Sydney Children's Hospital
RECRUITING

Randwick, New South Wales, 2031, Australia
Tan Tock Seng Hospital
RECRUITING

Singapore, 308433, Singapore
Tauranga Hospital
RECRUITING

Tauranga, 3112, New Zealand
The Children's Hospital at Westmead
RECRUITING

Westmead, New South Wales, 2145, Australia
The Ottawa Hospital - Civic Campus
RECRUITING

Ottawa, Ontario, K1H8L6, Canada
The Ottawa Hospital - General Campus
RECRUITING

Ottawa, Ontario, Canada
Toronto East Health Network - Michael Garron Hospital
RECRUITING

East York, Ontario, M4C3E7, Canada
Treant Ziekenhuis
RECRUITING

Emmen, Netherlands
UMC Groningen
ACTIVE_NOT_RECRUITING

Groningen, Netherlands
Unity Health - St Michael's Hospital
RECRUITING

Toronto, Ontario, M1L 1W1, Canada
Unity Health Toronto - St Joseph's Health Centre
RECRUITING

Toronto, Ontario, Canada
University College London Hospitals
RECRUITING

London, United Kingdom
University Health Network - Toronto General Hospital
COMPLETED

East York, Ontario, M5G2C4, Canada
University Health Network - Toronto Western Hospital
COMPLETED

Toronto, Ontario, Canada
University Hospital Carl Gustav Carus Dresden
RECRUITING

Dresden, Germany
University Hospital Southampton
RECRUITING

Southampton, United Kingdom
University Hospitals Birmingham
RECRUITING

Birmingham, United Kingdom
University Hospitals Bristol and Weston
RECRUITING

Bristol, United Kingdom
University Hospitals of North Midlands
NOT_YET_RECRUITING

Stoke, United Kingdom
University Medical Center Utrecht
RECRUITING

Utrecht, Netherlands
University Medical Centre Freiburg
RECRUITING

Freiburg im Breisgau, Germany
University of Alberta Hospital
RECRUITING

Edmonton, Alberta, T6G2B7, Canada
University of Sherbrooke Health Centre - Hospital Fleurimont
RECRUITING

Sherbrooke, Quebec, J1H 5H3, Canada
University of Sherbrooke Health Centre - Hotel Dieu
RECRUITING

Sherbrooke, Quebec, Canada
Vancouver General Hospital
RECRUITING

Vancouver, British Columbia, V5Z1M9, Canada
Waikato Hospital
RECRUITING

Hamilton, 3240, New Zealand
Wellington Hospital
RECRUITING

Newtown, Wellington Region, 6021, New Zealand
Western Health - Footscray, Joan Kirner & Sunshine Hospitals
RECRUITING

Footscray, Victoria, 3011, Australia
Westmead Hospital
RECRUITING

Westmead, New South Wales, 2145, Australia
Whangarei Hospital
NOT_YET_RECRUITING

Whangarei, 0148, New Zealand
Whittington Health
RECRUITING

London, United Kingdom
Wollongong Hospital
RECRUITING

Wollongong, New South Wales, 2500, Australia
Women and Children's Hospital
NOT_YET_RECRUITING

North Adelaide, South Australia, 5006, Australia
Women's and Children's Hospital
NOT_YET_RECRUITING

North Adelaide, South Australia, 5006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.